ORMP
Oramed Pharmaceuticals Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.01
+1.62%0
Insider buys (3m)
2
Insider sells (3m)
-$942.2K
Net value (3m)
+34.2%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Jul 2, 2026 | Hexter Joshua · officer: COO & CBO | M-Exempt | 50,000 | $3.69 |
| Jul 2, 2026 | Hexter Joshua · officer: COO & CBO | Sale | 137,000 | $4.46 |
| Jul 2, 2026 | Gabay Avraham · officer: Chief Financial Officer | Sale | 73,360 | $4.51 |
| Mar 31, 2026 | KIDRON NADAV · director, officer: President and CEO | F-InKind | 44,818 | $3.31 |
| Mar 31, 2026 | Kidron Miriam · director, officer: Chief Scientific Officer | F-InKind | 435,084 | $3.31 |
| Mar 18, 2026 | Kidron Miriam · director, officer: Chief Scientific Officer | A-Award | 119,558 | $0.00 |
| Mar 18, 2026 | Gabay Avraham · officer: Chief Financial Officer | A-Award | 95,889 | $0.00 |
| Mar 18, 2026 | Hexter Joshua · officer: COO & CBO | A-Award | 95,889 | $0.00 |
| Mar 18, 2026 | KIDRON NADAV · director, officer: President and CEO | A-Award | 167,005 | $0.00 |
| Jan 29, 2026 | Kidron Miriam · director, officer: Chief Scientific Officer | M-Exempt | 19,000 | $0.00 |
| Jan 29, 2026 | Gabay Avraham · officer: Chief Financial Officer | M-Exempt | 19,000 | $0.00 |
| Jan 29, 2026 | KIDRON NADAV · director, officer: President and CEO | M-Exempt | 109,000 | $0.00 |
| Jan 29, 2026 | Hexter Joshua · officer: COO & CBO | M-Exempt | 19,000 | $0.00 |
| Jan 5, 2026 | Reznick Yehuda · director | A-Award | 30,000 | $0.01 |
| Jan 5, 2026 | KIDRON NADAV · director, officer: President and CEO | A-Award | 327,000 | $0.00 |
| Jan 5, 2026 | KIDRON NADAV · director, officer: President and CEO | A-Award | 232,640 | $0.00 |
| Jan 5, 2026 | KIDRON NADAV · director, officer: President and CEO | A-Award | 109,000 | $0.00 |
| Jan 5, 2026 | Kidron Miriam · director, officer: Chief Scientific Officer | A-Award | 115,000 | $0.00 |
| Jan 5, 2026 | Kidron Miriam · director, officer: Chief Scientific Officer | A-Award | 121,331 | $0.00 |
| Jan 5, 2026 | Kidron Miriam · director, officer: Chief Scientific Officer | A-Award | 19,000 | $0.00 |
| Jan 5, 2026 | Hexter Joshua · officer: COO & CBO | A-Award | 115,000 | $0.00 |
| Jan 5, 2026 | Hexter Joshua · officer: COO & CBO | A-Award | 97,328 | $0.00 |
| Jan 5, 2026 | Hexter Joshua · officer: COO & CBO | A-Award | 19,000 | $0.00 |
| Jan 5, 2026 | Shapiro Benjamin · director | A-Award | 3,500 | $0.00 |
| Jan 5, 2026 | Shapiro Benjamin · director | A-Award | 30,000 | $0.01 |
| Jan 5, 2026 | Mayer Arie · director | A-Award | 4,900 | $0.00 |
| Jan 5, 2026 | Mayer Arie · director | A-Award | 30,000 | $0.01 |
| Jan 5, 2026 | Reznick Yehuda · director | A-Award | 6,250 | $0.00 |
| Jan 2, 2026 | Aghion Daniel · director | A-Award | 6,250 | $0.00 |
| Jan 2, 2026 | Aghion Daniel · director | A-Award | 30,000 | $0.01 |
Institutional positioning
13F filings over the trailing two quarters
New 17Increased 19Reduced 17Sold out 62
| Filer | Action | Shares | Filed |
|---|---|---|---|
| BML CAPITAL MANAGEMENT, LLC | Unchanged | 3,167,231 | May 6, 2026 |
| Aquamarine Financial (Cayman) Ltd | Increased | 2,112,312 | May 15, 2026 |
| MERCER GLOBAL ADVISORS INC /ADV | New Position | 1,910,540 | May 15, 2026 |
| GEM INVESTMENT ADVISORS, LLC | Reduced | 1,640,069 | May 15, 2026 |
| MURCHINSON LTD. | Reduced | 1,315,294 | May 15, 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | Reduced | 600,716 | May 15, 2026 |
| MARSHALL WACE, LLP | Increased | 259,611 | May 15, 2026 |
| RATHBONES GROUP PLC | Unchanged | 233,018 | Jun 9, 2026 |
| DIMENSIONAL FUND ADVISORS LP | Increased | 158,209 | May 7, 2026 |
| WELLS FARGO & COMPANY/MN | Increased | 157,586 | Jul 8, 2026 |
| RITHOLTZ WEALTH MANAGEMENT | New Position | 155,479 | Apr 20, 2026 |
| RENAISSANCE TECHNOLOGIES LLC | Increased | 147,700 | May 14, 2026 |
| BANK OF AMERICA CORP /DE/ | Increased | 146,152 | May 18, 2026 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | Increased | 136,218 | May 15, 2026 |
| O'SHAUGHNESSY ASSET MANAGEMENT, LLC | New Position | 116,363 | May 13, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Jul 2, 2026